206 related articles for article (PubMed ID: 35666466)
1. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.
Lin Y; Yue S; Yang Y; Yang S; Pan Z; Yang X; Gao L; Zhou J; Li Z; Hu L; Tang J; Wu Q; Lei S; Tian Q; Wang Y; Hao Y; Xu L; Huang Q; Zhu B; Chen Y; Chen X; Ye L
Clin Infect Dis; 2023 Feb; 76(3):e336-e341. PubMed ID: 35666466
[TBL] [Abstract][Full Text] [Related]
2. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.
Wang X; Chen X; Tan J; Yue S; Zhou R; Xu Y; Lin Y; Yang Y; Zhou Y; Deng K; Chen Z; Ye L; Zhu Y
Cell Host Microbe; 2022 Jun; 30(6):887-895.e4. PubMed ID: 35436443
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Liu Y; Zhang J; Liu W; Pan Y; Ruan S; Nian X; Chen W; Sun L; Yin Q; Yue X; Li Q; Gui F; Wu C; Wang S; Yang Y; Jing Z; Long F; Wang Z; Zhang Z; Huang C; Duan K; Liang M; Yang X
Emerg Microbes Infect; 2024 Dec; 13(1):2284297. PubMed ID: 37970736
[TBL] [Abstract][Full Text] [Related]
4. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.
Wang X; Hu A; Chen X; Zhang Y; Yu F; Yue S; Li A; Zhang J; Pan Z; Yang Y; Lin Y; Gao L; Zhou J; Zhao J; Li F; Shi Y; Huang F; Yang X; Peng Y; Tu L; Zhang H; Zheng H; He J; Zhang H; Xu L; Huang Q; Zhu Y; Deng K; Ye L
Signal Transduct Target Ther; 2022 Apr; 7(1):114. PubMed ID: 35383141
[TBL] [Abstract][Full Text] [Related]
5. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
[TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers.
Imsuwansri T; Jongthitinon T; Pojdoung N; Meesiripan N; Sakarin S; Boonkrai C; Wongtangprasert T; Phakham T; Audomsun T; Attakitbancha C; Saelao P; Muanwien P; Tian MT; Tongchusak S; Sangruji B; Wannigama DL; Sawangmake C; Rodprasert W; Le QD; Purbantoro SD; Vasuntrarak K; Nantavisai S; Sirilak S; Uppapong B; Sapsutthipas S; Trisiriwanich S; Somporn T; Usoo A; Mingngamsup N; Phumiamorn S; Aumklad P; Arunprasert K; Patrojanasophon P; Opanasopit P; Pesirikan N; Nitisaporn L; Pitchayakorn J; Narkthong T; Mahong B; Chaiyo K; Srisutthisamphan K; Viriyakitkosol R; Aeumjaturapat S; Jongkaewwattana A; Bunnag S; Pisitkun T
Sci Rep; 2023 Sep; 13(1):15648. PubMed ID: 37730833
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
[TBL] [Abstract][Full Text] [Related]
13. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
15. A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.
Kan Q; Lin X; Li T; Ke X; Jian X; Hou L; Zhang W; Wan Z; Xie Q; Shao H; Ye L; Ye J; Qin A; Zou Z; Chen Q
J Med Virol; 2023 Mar; 95(3):e28657. PubMed ID: 36912367
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
17. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
19. Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant.
Wen K; Cai JP; Fan X; Zhang X; Luo C; Tang KM; Shuai H; Chen LL; Zhang RR; Situ J; Tsoi HW; Wang K; Chan JF; Yuan S; Yuen KY; Zhou H; To KK
Front Cell Infect Microbiol; 2023; 13():1213806. PubMed ID: 37645378
[TBL] [Abstract][Full Text] [Related]
20. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
